DPP-4 Inhibitors Beyond Diabetes: Novel Therapeutic Applications Emerging
Review of DPP-4 inhibitors explores novel therapeutic applications beyond diabetes, including cardiovascular protection, neurodegeneration, and inflammatory conditions.
Quick Facts
What This Study Found
Review of DPP-4 inhibitors explores novel therapeutic applications beyond diabetes, including cardiovascular protection, neurodegeneration, and inflammatory conditions.
Key Numbers
Review covers six DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, and teneligliptin.
How They Did This
Methodology in publication.
Why This Research Matters
Relevant to peptide-based therapeutic applications.
The Bigger Picture
Contributes to peptide therapeutic evidence.
What This Study Doesn't Tell Us
Limitations in publication.
Questions This Raises
- ?Long-term implications?
- ?Comparison to evidence?
- ?Next research?
Trust & Context
- Key Stat:
- Key finding Review of DPP-4 inhibitors explores novel therapeutic applications beyond diabetes, including cardio
- Evidence Grade:
- Based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus.
- Published In:
- Pharmacoepidemiology and drug safety, 34(12), e70277 (2025)
- Authors:
- Aloke, Chinyere, Adelusi, Oluwasola Abayomi, Onisuru, Olalekan Olugbenga, Iwuchukwu, Emmanuel Amarachi, Achilonu, Ikechukwu
- Database ID:
- RPEP-09891
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Review of DPP-4 inhibitors explores novel therapeutic applications beyond diabetes, including cardiovascular protection, neurodegeneration, and inflammatory conditions.
How reliable?
Consult publication and provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09891APA
Aloke, Chinyere; Adelusi, Oluwasola Abayomi; Onisuru, Olalekan Olugbenga; Iwuchukwu, Emmanuel Amarachi; Achilonu, Ikechukwu. (2025). Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus.. Pharmacoepidemiology and drug safety, 34(12), e70277. https://doi.org/10.1002/pds.70277
MLA
Aloke, Chinyere, et al. "Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus.." Pharmacoepidemiology and drug safety, 2025. https://doi.org/10.1002/pds.70277
RethinkPeptides
RethinkPeptides Research Database. "Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents ..." RPEP-09891. Retrieved from https://rethinkpeptides.com/research/aloke-2025-dipeptidyl-peptidase-4-inhibitors
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.